-
2025-522832-16-00
10
Severe trauma
-
2025-522949-22-00
5
Duchenne muscular dystrophy
-
2025-523094-42-00
5
Hirschsprung's disease
-
2025-523149-80-00
10
Adult patients admitted to the ICU and receiving unplanned invasive me
-
2025-523481-24-00
5
Participants with Progressive Supranuclear Palsy Richardson Syndrome (
-
2025-523555-66-00
5
Myelofibrosis
-
2025-523579-47-00
4
moderate to severe rheumatoid arthritis (RA)
-
2025-523750-14-00
5
refractory hypotension in distributive shock
-
2025-524316-11-00
5
Primary Progressive Multiple Sclerosis (PPMS)
-
2025-524367-20-00
4
Adult patients with primary mitochondrial disease
-
2025-522255-25-00
5
2026-05-18
Fallopian Tube Neoplasms
-
2025-524160-38-00
5
2026-05-12
Renal Cell Carcinoma, hepatocellular carcinoma, nonMSI-H/dMMR colorect
-
2023-508047-40-00
5
2026-04-30
Ovarian cancer
-
2024-514006-31-00
9
2026-04-16
Non-active Progressive Multiple Sclerosis (PMS)
-
2025-522279-27-00
5
2026-04-02
Newly Diagnosed AML with an NPM1 mutation
-
2024-519555-28-00
5
2026-03-18
Dravet syndrome
-
2024-519444-33-00
5
2026-03-12
HER2-expressing endometrial cancer (IHC 3+/2+)
-
2024-513911-28-00
10
2026-03-04
Acute Ischemic Stroke
-
2024-520222-11-00
3
2026-03-03
Hematological or solid tumor malignancies or autoimmune diseases
-
2025-521514-26-00
5
2026-01-26
Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2023-507525-42-00
5
2025-12-23
Endometrial cancer
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-